FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003553242> ?p ?o ?g. }

• W2003553242 endingPage "590" @default.
• W2003553242 startingPage "583" @default.
• W2003553242 abstract "The second-generation antipsychotics are associated with metabolic abnormalities in patients with schizophrenia. Elderly patients with Alzheimer's disease are frequently treated with these antipsychotics, but limited data are available on their metabolic effects.The authors assessed 186 male and 235 female Alzheimer's disease outpatients from the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer's Disease (CATIE-AD) for changes in weight, waist circumference, blood pressure, fasting glucose, and lipids in relation to duration of second-generation antipsychotic use (i.e., olanzapine, quetiapine, and risperidone) throughout the 36-week trial, using logistic regression and mixed-effects models.Women showed significant weight gain (0.14 lb/week of use) while change was nonsignificant in men. Clinically significant weight gain (i.e., > or = 7% of body weight) was seen among patients with antipsychotic use < or = 12 weeks (odds ratio [OR]=1.56, 95% CI=0.53 to 4.58), between 12 and 24 weeks (OR=2.89, 95% CI=0.97 to 8.64), and > 24 weeks (OR=3.38, 95% CI=1.24 to 9.23) relative to patients who did not use antipsychotics during the trial. Olanzapine and quetiapine treatments were significantly associated with weight gain (0.12 and 0.14 lb/week, respectively). In addition, olanzapine was significantly associated with decreases in HDL cholesterol (-0.19 mg/dl/week) and increased girth (0.07 inches/week) relative to the placebo group. No treatment effects were noted for changes in blood pressure, glucose, and triglycerides.Second-generation antipsychotic use was associated with weight gain in women, with olanzapine and quetiapine in particular, and with unfavorable change in HDL cholesterol and girth with olanzapine. The potential consequences of these effects suggest that patients with Alzheimer's disease treated with second-generation antipsychotics should be monitored closely." @default.
• W2003553242 created "2016-06-24" @default.
• W2003553242 creator A5002451678 @default.
• W2003553242 creator A5005674169 @default.
• W2003553242 creator A5018782725 @default.
• W2003553242 creator A5020042179 @default.
• W2003553242 creator A5023756758 @default.
• W2003553242 creator A5032755820 @default.
• W2003553242 creator A5036507830 @default.
• W2003553242 creator A5036718203 @default.
• W2003553242 creator A5047243813 @default.
• W2003553242 creator A5053223016 @default.
• W2003553242 creator A5059020389 @default.
• W2003553242 date "2009-05-01" @default.
• W2003553242 modified "2023-10-04" @default.
• W2003553242 title "Metabolic Changes Associated With Second-Generation Antipsychotic Use in Alzheimer’s Disease Patients: The CATIE-AD Study" @default.
• W2003553242 cites W163960231 @default.
• W2003553242 cites W1867692464 @default.
• W2003553242 cites W1948712038 @default.
• W2003553242 cites W1965041597 @default.
• W2003553242 cites W1972809085 @default.
• W2003553242 cites W1985675058 @default.
• W2003553242 cites W1990224774 @default.
• W2003553242 cites W1993818042 @default.
• W2003553242 cites W2004122611 @default.
• W2003553242 cites W2012355684 @default.
• W2003553242 cites W2032837774 @default.
• W2003553242 cites W2033610699 @default.
• W2003553242 cites W2050721184 @default.
• W2003553242 cites W2052136081 @default.
• W2003553242 cites W2060153776 @default.
• W2003553242 cites W2084561734 @default.
• W2003553242 cites W2112815097 @default.
• W2003553242 cites W2125346945 @default.
• W2003553242 cites W2132592055 @default.
• W2003553242 cites W2132871355 @default.
• W2003553242 cites W2139560403 @default.
• W2003553242 cites W2157331971 @default.
• W2003553242 cites W2159155203 @default.
• W2003553242 cites W2162993517 @default.
• W2003553242 cites W2169849640 @default.
• W2003553242 cites W2170210994 @default.
• W2003553242 cites W2304312977 @default.
• W2003553242 cites W2740979 @default.
• W2003553242 doi "https://doi.org/10.1176/appi.ajp.2008.08081218" @default.
• W2003553242 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2891018" @default.
• W2003553242 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19369318" @default.
• W2003553242 hasPublicationYear "2009" @default.
• W2003553242 type Work @default.
• W2003553242 sameAs 2003553242 @default.
• W2003553242 citedByCount "75" @default.
• W2003553242 countsByYear W20035532422012 @default.
• W2003553242 countsByYear W20035532422013 @default.
• W2003553242 countsByYear W20035532422014 @default.
• W2003553242 countsByYear W20035532422015 @default.
• W2003553242 countsByYear W20035532422016 @default.
• W2003553242 countsByYear W20035532422017 @default.
• W2003553242 countsByYear W20035532422018 @default.
• W2003553242 countsByYear W20035532422019 @default.
• W2003553242 countsByYear W20035532422020 @default.
• W2003553242 countsByYear W20035532422021 @default.
• W2003553242 countsByYear W20035532422022 @default.
• W2003553242 countsByYear W20035532422023 @default.
• W2003553242 crossrefType "journal-article" @default.
• W2003553242 hasAuthorship W2003553242A5002451678 @default.
• W2003553242 hasAuthorship W2003553242A5005674169 @default.
• W2003553242 hasAuthorship W2003553242A5018782725 @default.
• W2003553242 hasAuthorship W2003553242A5020042179 @default.
• W2003553242 hasAuthorship W2003553242A5023756758 @default.
• W2003553242 hasAuthorship W2003553242A5032755820 @default.
• W2003553242 hasAuthorship W2003553242A5036507830 @default.
• W2003553242 hasAuthorship W2003553242A5036718203 @default.
• W2003553242 hasAuthorship W2003553242A5047243813 @default.
• W2003553242 hasAuthorship W2003553242A5053223016 @default.
• W2003553242 hasAuthorship W2003553242A5059020389 @default.
• W2003553242 hasBestOaLocation W20035532422 @default.
• W2003553242 hasConcept C118552586 @default.
• W2003553242 hasConcept C126322002 @default.
• W2003553242 hasConcept C134018914 @default.
• W2003553242 hasConcept C142724271 @default.
• W2003553242 hasConcept C147583825 @default.
• W2003553242 hasConcept C204787440 @default.
• W2003553242 hasConcept C27081682 @default.
• W2003553242 hasConcept C2776412080 @default.
• W2003553242 hasConcept C2776619155 @default.
• W2003553242 hasConcept C2776921671 @default.
• W2003553242 hasConcept C2780057945 @default.
• W2003553242 hasConcept C2780320433 @default.
• W2003553242 hasConcept C2780494398 @default.
• W2003553242 hasConcept C2780634440 @default.
• W2003553242 hasConcept C3017894415 @default.
• W2003553242 hasConcept C511355011 @default.
• W2003553242 hasConcept C544821477 @default.
• W2003553242 hasConcept C71924100 @default.
• W2003553242 hasConceptScore W2003553242C118552586 @default.
• W2003553242 hasConceptScore W2003553242C126322002 @default.
• W2003553242 hasConceptScore W2003553242C134018914 @default.
• W2003553242 hasConceptScore W2003553242C142724271 @default.

• next